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ABSTRACT 
BACKGROUND:  Economic evaluation of health care has developed into a sub- 
stantial body of work, and its contribution to medical decision making is increasingly 
being recognized. 
OBJECTIVE: The aim of the study was to describe the characteristics and quality 
of health economic (including pharmacoeconomic) evaluation research studies related 
to Zimbabwe. 
METHODS: A review of the literature was conducted to identify published health 
economic evaluation studies related to Zimbabwe. HEED, PubMed, MEDLINE, 
HealthSTAR, EconLit, and PsycINFO databases and sociological and dissertation 
abstracts were used to search for economic analyses. The searches used the following 
terms alone and in combination: costs, budgets, fee, economics, health, pharmacy, pharmacy 
services, medicines, drugs, health economics, ost-effectiveness, co t-benefit, cost-minimization, cost 
utility analysis, and Zimbabwe. Only original applied economic evaluations addressing 
a health-related topic pertaining to Zimbabwe and published in full were included. 
Two reviewers independently evaluated and scored each study in the final sample 
using the data collection form designed for the study. 
RESULTS:  Fifty-nine studies were identified in the database searches, 18 of 
which were excluded because they were not about Zimbabwe (3 studies) or were not 
health related (15). Of the 41 remaining studies, 8 were excluded after further eview 
because they were not original research, 6 because they were not economic analyses, 
and 1 because it was not about Zimbabwe. The final 26 studies appeared in 13 differ- 
ent journals (based mostly [17 (65%)] outside of Zimbabwe). The mean (SD) number 
of authors of each study was 3.36 (2.13); most of the authors had medical/clinical 
training. The number of studies peaked between 1994 and 1997. Based on a 10-point 
scale, with 10 indicating the highest quality, the mean (SD) quality score for all stud- 
ies was 5.40 (1.56); 8 of the studies (31%) were considered to be of poor quality (score 
<4). The quality of the studies reviewed was significantly (all, P < 0.05) associated 
with the country in which the journal was based (non-Zimbabwe = higher), the pri- 
mary health intervention (services > pharmaceutical interventions), the number of 
authors (more authors = higher), and year of publication (more recent = higher). 
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CONCLUSION:  This study indicated that the use of health economic (including 
pharmacoeconomic) evaluation research in Zimbabwe was low, and 31% of the studies 
were of poor quality. More and better quality health economic research in Zimbabwe 
is warranted. (Curr Ther Res Clin Exp. 2008;69:268-285) © 2008 Excerpta Medica 
Inc. 
Kwy WORDS:  cost-effective analysis, health economics, pharmacoeconomics, eco- 
nomic evaluation, quality assessment, Zimbabwe. 
INTRODUCTION 
Economic evaluation of health care has developed into a substantial body of work, and 
its contribution to medical decision making is increasingly being recognized. 1 In the 
worldwide medical literature, the number of publications relating to economic analy- 
ses of health care programs, including pharmaceuticals, has increased. The use of reli- 
able, timely health economic evaluation data is helpful in making optimal policy 
decisions regarding the allocation of health care resources and enhances the pursuit of 
cost-effective medical excellence. 
There have been concerns about the quality of some health economic (in this study, 
considered to always include pharmacoeconomics) studies published in the medical lit- 
erature; many published studies are of poor quality. 2"3 This challenge is expected to be 
more pronounced in developing countries that have ineffective, poorly financed health 
systems. Developing countries, including Zimbabwe, face many challenges to conduct- 
ing good quality economic evaluation studies, resulting in their limited availability, v 8 
The Zimbabwean economy suffers from high inflation, poverty, unemployment, 
and persistent foreign currency and food shortages. 9 The negative macroeconomic 
environment, ogether with high unemployment (60%), high poverty levels (65%), 
and high HIV/AIDS prevalence (18%) have reduced the standard of health among the 
majority of Zimbabweans and have widened the gap between the rising demand for 
health care (including pharmaceuticals) and the shrinking national resources. 9-11 
Concerns over the rising costs of health care in Zimbabwe have been growing.l°,12-14 
Health interventions in the country may be inefficient and ineffective. To date, no 
effort has been made to analyze the economic evaluation studies that have been con- 
ducted in Zimbabwe. Despite the recognized importance of cost data in health care 
planning, there is little information on the cost-effectiveness of Zimbabwean health 
care delivery. 15 
The present study assessed the state of health economic evaluation research studies 
about Zimbabwe published between 1987 and 2005. We sought o describe the study 
characteristics and to assess their quality and quantity. 
METHODS 
An initial literature search was conducted in September 2006 (and updated in March 
2007) to identify published economic evaluation studies pertaining to Zimbabwe. 
HEED, PubMed, MEDLINE, HealthSTAR, EconLit, and PsyclNFO databases and 
sociological and dissertation abstracts were used to search for economic analyses. The 
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searches used the following terms alone and in combination: costs, budgets, fee, economics, 
health, pharmacy, pharmacy services, medicines, drugs, health economics, cost-effectiveness, co t- 
benefit, cost-minimization, cost utility analysis, and Zimbabwe. Additional studies were 
identified from reference lists of the obtained studies. This continued for all the addi- 
tional studies until no more new studies could be identified. 
This review included only original economic evaluations that pertained to 
Zimbabwe, addressed a health-related topic (eg, pharmacy, nursing), and were pub- 
lished in full (eg, no abstracts). Abstracts of the studies that met the inclusion and 
exclusion criteria were assessed by 2 reviewers who were blinded to each other's work. 
Studies that met all of the inclusion criteria were reviewed. The selected studies were 
obtained for full evaluation from university libraries in the United States and 
Zimbabwe and through interlibrary loan. 
EVALUATION OF STUDIES  AND INFORMATION EXTRACTION 
A data collection form was designed based on existing economic guidelines 16,17 and 
on previous work by Zarnke et a118 and Offman et al. 19 Two reviewers independently 
evaluated and scored each study using this data collection form. A third researcher, 
serving as a tiebreaker, ead and scored the items about which the 2 primary reviewers 
disagreed. The data collection form included general information (eg, the number of 
authors, country of residence of the first author, primary training of the first author, 
and year of publication of the study), economic analysis information (eg, the study's 
primary outcomes, whether or not economic evaluation was the primary objective, the 
study's perspective, and the study design), and a subjective rating of the quality of the 
study. The reviewers provided an overall assessment of the quality of each of the studies 
based on a 10-point scale (1 = lowest quality to 10 = highest quality). The reviewers 
considered all the strengths and weaknesses of the study in determining their rating. 
Scores were collapsed into 3 groups: poor = 1 to 4; fair = 5 to 7; and good = 8 to 10. 
The most appropriate instrument for assessing the quality of economic analyses i  
the validated quality of health economic studies (QHES) instrument. 19The data col- 
lection form contained questions from the QHES instrument, which is intended to 
assess the overall quality of full economic analyses. However, given that only 3 of the 
26 studies were full economic evaluations, the QHES scores were not used in compar- 
ing the quality of the studies. 
STAT IST ICAL  ANALYS IS  
The ratings of the 2 reviewers were compared for all studies. The number of times 
the reviewers agreed was noted for each item and was reported as a percentage. 
Through post hoc training and the intervention of the tiebreaker, the reviewers were 
able to agree on 1 coded response for each item. The correlation between the reviewers' 
10-point subjective quality score ratings of the studies was assessed using the Spearman 
rank correlation. A mean of the 2 reviewers' quality scores for each study was calculated 
and was used for all further analyses whenever a quality score was needed. 
Descriptive statistics were calculated and reported for all variables. The t tests and 
analyses of variance were conducted to determine if there were significant differences 
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in the mean quality of the studies by various categories (country of journal, type of 
publication, primary objective, type of data), if a category had ->5 observations. The 
Pearson correlation coefficient was used to investigate the relationship between the 
quality score and the number of authors, the year of publication, and sample size. All 
statistical analyses were performed using SPSS version 14.0 (SPSS Inc., Chicago, 
Illinois). P < 0.05 was considered statistically significant. 
RESULTS 
Fifty-nine studies, all of which were written in English, were identified in the data- 
base searches. Eighteen studies were excluded because they were not about Zimbabwe 
(3) or were not directly health related or original economic analyses (15) (Table I). Of 
the remaining 41 studies, 8 were excluded because they were not original research, 
6 because they were not economic analyses, and 1 because it was not about Zimbabwe 
(although it was published in Zimbabwe) (Table II). The final literature sample 
consisted of 26 economic evaluation studies 1°,12-15,2°-4° that satisfied the inclusion 
criteria (Table III and Figure 1). 
INTERRATER AGREEMENT 
Agreement between the reviewers ranged from a minimum of 77% to a maximum 
of 100% per item (mode = 100%). There was high agreement between raters on all 
primary variables, such as the method of economic evaluation as defined by the 
authors (88%), the method of economic evaluation as rated by reviewers (77%), the 
primary objective of the economic evaluation (81%), and the decision reached on cost- 
effectiveness (100%). Spearman rank correlation showed that there was a high and 
positive statistically significant correlation between the reviewers' quality scores on 
the 10-point subjective scale (r = 0.83; n = 26; P < 0.001). 
CHARACTERIST ICS  OF' THE ECONOMIC I~VALUATION STUDIES  
The 26 studies 1°,12-15,2°-4° we reviewed were published in 13 different journals 
that were based in 4 different countries. Nine of the studies (35%) were published in 
Zimbabwe, and the majority of the remainder were published in journals based in the 
United Kingdom and the United States. Nineteen studies (73%) were published in 
medical journals and 7 (27%) were published in nonmedical journals. No study was 
published in a health/medical economics journal (including pharmacoeconomics jour- 
nals) (Table IV). Seven studies 12,21,29,31,32,36,4° (27%) were published in The Central 
African Journal of Medicine, which is based in Zimbabwe. 
The mean (SD) number of authors per study was 3.36 (2.13) (range, 1-9). Eighteen 
of the corresponding authors (69%) resided in Zimbabwe at the time the study was 
published, and the majority of the remaining corresponding authors resided in the 
United States (5) and United Kingdom (2). Fourteen of the first authors (54%) had 
medical/clinical training and 7 (27%) had nonmedical training. Sixteen studies 
(62%) covered a portion of 1 country, 7 studies (27%) were national, and 3 studies 
(12%) were multinational (Table IV). The sample sizes ranged from a minimum of 
22 to a maximum of 16,063 participants. 
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Citations identified by database searches 
(N = 59) 
. Excluded according to the inclusion criteria I 
after screening abstracts (18) 1 
Potential cost and economic studies 
(n = 41) 
Excluded according to the inclusion criteria 
after screening entire article (15) 
I Final sample of economic analyses (n = 26) 
Cost analyses (23) 
Full economic analyses (3) 
Figure 1. Flow chart of the manuscript selection process. 
Sixteen studies (62%) did not list the source of funding. Of the 10 studies that 
listed the funding source, 6 (60%) were funded by private nonprofit organizations and 
1 (10%) was funded by the pharmaceutical industry. The government payer (14 
[54%]) was the dominant study perspective. Seventeen studies (65%) collected pri- 
mary data and 8 (31%) used secondary data sources; the type of data could not be 
determined for 1 study (Table IV). Ten studies (38%) did not investigate a specif- 
ic disease. HIV/AIDS was the most frequently (9 [35%]) investigated is- 
ease. 1°,13,14,22,24,2%2~,3°,33 Each of the following diseases was investigated in 1 study: 
hypertension, 29urinary schistosomiasis, 31 Neisseria gonorrhoeae, 21 pulmonary tuberculosis/ 
malaria, 24 and reproductive tract infection. 39 
EXTENT AND TREND OF ECONOMIC EVALUATION STUDIES 
There were 23 cost studies (88%) and 3 full economic evaluation studies (12%), all 
of which were cost-effectiveness analyses (CEAs). Only 1 of these 3 studies was cor- 
rectly labeled as such by the authors. Economic evaluation was the primary objective 
of 18 studies (69%) (Table IV). Twelve studies (46%) were about pharmaceuticals, 7 
(27%) were about services, and the remaining 7 (27%) were about other health inter- 
ventions. Treatment (12 [46%]) and prevention and screening (6 [23%]) were the 
most investigated medical functions. 
The earliest study 36 was published in 1987 and the latest study 34 was published 
in 2005. The highest number of studies 2°,21,27,28 published in a given year (4) was in 
1995. The number of studies peaked between 1994 and 1997 and declined slightly 
thereafter (Figure 2). A mean (SD) of 3.21 (1.65) years (range, 1-7 years) elapsed 
between the year of publication of the study and the last year of data collection. 
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Table IV. Relationships between quality scores and study characteristics (N = 26). 
No. of Quality Score,* 
Characteristic Studies Mean (SD) 
Country in which the journal was basedt 
Zimbabwe 9 4.44 (1.36) 
Outside Zimbabwe 17 5.91 (1.44) 
Type of publication 
Medical 19 5.05 (1.54) 
Nonmedical 7 6.36 (1.22) 
Country of current residence of lead author 
Zimbabwe 18 5.17 (1.48) 
Other 8 5.94 (1.70) 
Primary training of the lead author 
Medical 14 5.46 (1.50) 
Nonmedical 7 5.79 (1.78) 
Undetermined 5 4.70 (1.48) 
Geographic location covered in the study~ 
Portion of 1 country 15 5.10 (1.63) 
National 8 5.50 (1.51) 
Multinational 3 6.67 (0.76) 
Primary source of funding~§ 
Private nonprofit organization 6 6.00 (0.89) 
Government 2 5.75 (3.18) 
Pharmaceutical industry 1 - 
Not listed 16 5.03 (1.64) 
Study perspective~ 
Government payer 14 5.14 (1.68) 
Private payer 3 4.50 (0.50) 
Patient 2 4.75 (2.47) 
Not provided 7 6.33 (0.82) 
Type of data used~[ 
Primary 17 5.09 (1.49) 
Secondary 8 5.75 (1.49) 
Method of economic evaluationt 
Cost analysis 23 5.15 (1.46) 
Cost-effectiveness analysis 3 7.33 (0.76) 
Was economic evaluation the primary objective? 
Yes 18 5.61 (1.55) 
No 8 4.94 (1.57) 
Primary health interventiontll 
Pharmaceuticals 12 4.75 (1.32) 
Services 7 6.29 (1.32) 
Other 7 6.08 (1.53) 
(continued) 
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Table IV. (Continued) 
No. of Quality Score,* 
Characteristic Studies Mean (SD) 
Study design ~r 
Retrospective design 9 4.67 (1.67) 
Modeling 4 7.13 (0.75) 
Other 13 5.39 (1.31) 
Continuous variables Pearson Correlation, r 
No. of authorst 26 0.420 
Year of publicationt 26 0.375 
Sample size 17 -0.215 
*Scale: 1 = lowest quality to 10 = highest quality. 
tp < 0.05. 
~Cell sizes too small for statistical comparison. 
§One study indicated the authors used their own resources. 
¶Type of data used could not be determined for 1 study. 
IIPost hoc analysis of variance indicated mean quality score for Services was significantly higher than 
that of Pharmaceuticals and Other. 
QUALITY OF HEALTH ECONOMICS INFORMATION IN THE STUDIES 
The mean (SD) quality score for all 26 studies was 5.40 (1.56) and ranged from 3 
to 9. Eight studies (31%) were of poor quality (score _<4), 15 (58%) were of fair quality 
(score 5-7), and 3 (12%) were of good quality (_>8). 
4 
3 
2 'S 
I'-- O0 0") 0 ~1CN O0 ~" LO (g I". O00~ 0 ~1C~I C~ ~" LO 
O0 O0 O00~ O~ 0") O~ O~ 0") 0") 0"~ 0") O~ 0 0 0 0 0 0 
0") 0") 0") O~ 0") 0") 0") O~ O~ 0") O~ 0") 0") 0 0 0 0 0 0 
Year of Publication 
Figure 2. Number of economic evaluation studies published about Zimbabwe between 
1987 and 2005.  
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The quality of the studies was significantly related (all, P < 0.05) to the country in 
which the journal was based (non-Zimbabwe =higher), primary health intervention 
(services > pharmaceutical interventions), number of authors (more authors = higher), 
and year of publication (more recent = higher). Quality was not related to the country 
of residence of the primary author, type of publication, primary objective, type of data 
used, primary training of the first author, or sample size. Sample sizes were not large 
enough to conduct statistical comparisons on method of economic evaluation, geo- 
graphic location covered in the study, study perspective, study design, or primary 
source of funding (Table IV). 
The reviewers identified the following additional shortcomings that, in their opin- 
ion, compromised the quality of the studies: (1) did not specify when data collection 
was undertaken (6 studies); (2) did not specify the study's perspective (7); (3) had a 
methods ection that was not clearly written (1); (4) did not explicitly discuss direc- 
tion and magnitude of potential biases (1); (5) did not conduct sensitivity analyses (1); 
(6) failed to perform incremental nalysis when needed (1); and (7) failed to discount 
the benefits and costs that extended beyond 1 year (1). 
DISCUSSION 
CHARACTERIST ICS  OF THE ECONOMIC EVALUATION STUDIES  ABOUT Z IMBABWE 
Although all of the studies in this review were about Zimbabwe, most (17 [65%]) 
of them were published in journals based outside Zimbabwe. This might be explained 
by the absence of specialized health journals in Zimbabwe. Publishing studies outside 
Zimbabwe increases the chances of rejection and greatly limits the dissemination of
the studies within Zimbabwe, as many Zimbabweans may not have access to journals 
published outside the country. 41 The proportion of studies published in Zimbabwe 
(35%) was similar to the proportion of studies published in domestic journals (33%) 
in Thailand, also a developing country, between 1982 and 2005. 42 The majority of 
studies in our review were written by primary authors who resided in Zimbabwe at 
the time the study was published, and most had medical/clinical training. It is note- 
worthy that most of the studies were published in medical journals and none were 
published in a health economics or pharmacoeconomics journal. 
The dominance of the government in health care in Zimbabwe was also reflected 
in the economic evaluations, as 50% of the studies we reviewed had a government 
payer perspective. The fact that many of the studies in our review did not list the 
primary source of funding is worrisome, raising concerns about ransparency. Only i study 
was reported to have been funded by the pharmaceutical industry. 
EXTENT AND TREND OF ECONOMIC EVALUATION STUDIES ABOUT Z IMBABWE 
The total number of economic evaluation studies published in Zimbabwe over the 
18-year period (1987-2005) covered in our study was small. In addition, most of the 
studies were cost studies, with only 3 being full economic evaluation studies. Only 1 
of the full evaluations assessed a pharmaceutical intervention. The number of topics 
and diseases investigated in the economic evaluations in Zimbabwe were limited; 
most of the studies of specific diseases were related to HIV/AIDS. This was expected, 
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given the high HIV/AIDS prevalence in the country (24%) and in many other devel- 
oping countries. 1° Teerawattananon et a142 found a similar pattern in Thailand, with 
50% of the health economics tudies being related to infectious diseases, including 
HIV/AIDS. 
There were no studies regarding some of the other major health problems in the 
country (eg, injury, mental disorders, diabetes mellitus, and perinatal conditions). The 
few areas covered by the studies and the low number of studies about pharmaceuticals 
indicate that health economic evaluation is still in its infancy in Zimbabwe. Our find- 
ings confirmed the results of Walker and Fox-Rushby 7 and Lee et al, 8 who found a 
limited supply of good quality economic evaluation studies in developing countries. 
Based on the small number of publications found, it appears that health policies and 
plans in Zimbabwe are being made without sound economic evaluation data, which 
confirms findings by Maynard. 43 The absolute number of health economic evaluation 
studies about Zimbabwe was low compared with such studies about the United 
Kingdom, Australia, the United States, and Canada, where economic analyses are 
formally used in health policy formulation. 19,44~ The number was low even when 
compared to the number of studies published in other developing countries, such as 
Thailand 42 (39 full economic evaluations, including 27 CEAs) and Korea s (33 full 
economic evaluations, including 14 CEAs). 
The study found that CEA was the most popular type of method of economic 
evaluation used. No study used other economic evaluation methods (eg, cost-benefit 
analysis or cost-utility analysis). Similarly, Teerawattananon et a142 found that CEA 
was the most popular (full economic) study type in Thailand, and Lee et al 8 found 
equal numbers of CEA (14/45 [31%]) and cost-benefit analysis (14/45 [31%]) studies 
in Korea. Without a national requirement for submission of economic data as part of 
the drug regulatory process in Zimbabwe, there is little incentive for stakeholders to
conduct full economic appraisals or evaluations. Numerous factors and constraints 
might be affecting the paucity of economic evaluations in Zimbabwe (eg, clinicians' 
lack of appreciation of economic evaluations, misconceptions about economic evalua- 
tions, the organization and payment structure of the health care system, and lack of 
expertise in economic evaluation). Moreover, conducting health economic evaluations 
is expensive and time consuming. 
The number of studies increased with time and peaked in the mid-1990s. This 
coincided with the increased importance of cost recovery, increased cost of care, and 
shrinking budgets allocated to health in the public sector during this period. This 
period was also characterized by a widening gap between costs and available resources, 
increased use of new and expensive medicines and technologies, the high prevalence 
of endemic diseases, and efforts by the government and private payers to maximize 
value for money, l° These developments might have influenced the increase in the 
number of economic evaluations conducted uring that period. 
QUAL ITY  OF  THE ECONOMIC INFORMATION IN THE STUDIES  
We found that a large percentage (31%) of the studies we reviewed were of poor 
quality, and only 3 of the 26 studies (12%) were of good quality. Although these 
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estimates of the number of quality studies may be debatable because they were 
subjective, the gap between what is known to constitute good quality studies and 
the characteristics of the studies we found was substantial enough to warrant 
attention. Our findings concur with findings of Gerard, 2 Udvarhelyi et al, 3 and 
Adams et al, 4 who reported that many published studies in general were of poor 
quality. The large number of poor studies might be explained by lack of expertise 
and limited knowledge about economic evaluation among clinicians, policy mak- 
ers, and managers, given that Zimbabweans may not have local training opportu- 
nities in health economics. The low quality of the studies might be compromising 
the usefulness of health economic evaluation research in policy formulation in 
Zimbabwe. 
The quality of the studies was significantly associated with the country in which 
the journal was based, the primary health intervention, the number of authors, and 
the year of publication. Although Neumann et a148 and Gerard et a149 reported that 
clinical specialty journals had higher chances of publishing poor quality economic 
studies, we found the association between the quality of the studies and type of pub- 
lication was not statistically significant. 
RECOMMENDATIONS AND IMPL ICAT IONS 
There is evidently great potential for increasing the quantity and improving the 
quality of economic evaluations to inform health policy and planning in Zimbabwe. 
Increasing health costs in Zimbabwe make the need for economic analysis even more 
urgent. Possible strategies for improving economic evaluations include increasing the 
awareness of and expertise in health economic evaluation through short-term courses 
and seminars. The incorporation of health economics and pharmacoeconomics in the 
undergraduate raining curriculum may help solve the problem. Neumann et a148 
underscored the need for educational efforts to improve the quality and quantity of 
future studies. If the value of these studies increases to the users, more studies will be 
undertaken and will have funding support. 
In the authors' opinion, there is a need to build an infrastructure that supports and 
nurtures health economic evaluation. The use of economic evaluation in health care 
requires at least a structure of priority setting, research facilities, and procedures for 
synthesizing and disseminating results. 
Improvement of the peer review process and better quality control by medical 
journal editors is essential in Zimbabwe and beyond. The peer review process has been 
shown to be a critical element in improving the quality of published studies. 5° 
The adoption of health economic guidelines would help standardize the conduct of 
future health economic evaluations in Zimbabwe. Such standardization would also 
help improve the quality of the studies, reduce bias, and increase the comparability of
the studies. Bell et a151 recommend that medical journals hould follow and adhere to 
health economic evaluation guidelines and checklists to improve the quality of the 
manuscripts hey publish. 
More research studies are needed to investigate the impact and contribution of 
health economic studies to policy formulation in Zimbabwe. 
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L IM ITAT IONS 
The results of this study might have been affected by some internal and external 
limitations. Although every attempt was made to include all relevant studies, it is 
possible that some published studies were missed or omitted. The choice and use of 
only studies published in full excluded studies in abstract or manuscript form, there- 
fore introducing publication bias. Selection bias was likely, as studies with positive 
results are more likely to be published in journals than studies with negative findings. 
In addition, the methods ection of some studies did not clearly describe what was 
done, making it difficult to categorize and code them; other readers may categorize 
them differently. Although the correlation between reviewers' quality ratings was 
high, these were subjective ratings. 
CONCLUSION 
Despite the pressure on the government, third party payers, and hospitals to address 
the high and increasing cost of health care in Zimbabwe, our study found that the use 
of health economic (including pharmacoeconomic) evaluation research from 1987 to 
2005 was limited. Only 26 cost and outcome analyses, mainly of poor or fair quality, 
were conducted, and these were targeted at 6 specific health problems. Measures are 
needed to promote the commissioning ofmore and better quality health economic and 
pharmacoeconomic evaluation studies in Zimbabwe and to promote the use of their 
results in policy formulation. 
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